All Stories

  1. A New Perspective in Utilizing MMP-9 as a Therapeutic Target for Alzheimer’s Disease and Type 2 Diabetes Mellitus
  2. Pharmacogenetic Inhibition of eIF4E-Dependent Mmp9 mRNA Translation Reverses Fragile X Syndrome-like Phenotypes
  3. Neuroprotective role of MMP-9 overexpression in the brain of Alzheimer's 5xFAD mice
  4. ECM in brain aging and dementia
  5. Neural ECM proteases in learning and synaptic plasticity
  6. An apolipoprotein E4 fragment affects matrix metalloproteinase 9, tissue inhibitor of metalloproteinase 1 and cytokine levels in brain cell lines
  7. Enhanced neuronal plasticity and elevated endogenous sAPPα levels in mice over‐expressing MMP9
  8. Expression levels of matrix metalloproteinase (MMP)-9 and its specific inhibitor TIMP-1, in septic and aseptic arthritis of the knee
  9. TIMP-1 interaction with αvβ3 integrin confers resistance to human osteosarcoma cell line MG-63 against TNF-α-induced apoptosis
  10. An apolipoprotein E4 fragment can promote intracellular accumulation of amyloid peptide beta 42
  11. Abeta(1–40)-induced secretion of matrix metalloproteinase-9 results in sAPPα release by association with cell surface APP
  12. Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells
  13. Proximal Tubular Epithelial Cell Integrins Respond to High Glucose by Altered Cell-Matrix Interactions and Differentially Regulate Matrixin Expression
  14. Effects of Collagen IV on Neuroblastoma Cell Matrix-Related Functions
  15. Identification and molecular characterization of a putative histone H1-like transcription factor in leishmania
  16. Solution structures of the fibronectin-like Leishmania gp63 SRYD-containing sequence in the free and antibody-bound states . Transferred NOE and molecular dynamics studies
  17. TR-NOE and MD studies ofLeishmania gp63 SRYD-containing sequences bound to anti-SRYD monoclonal antibody
  18. Conformational and antigenic properties of SRYD-containing peptide analogues of Leishmania gp63 adhesion site
  19. Structural profile of SRYD-containing peptide analogues of Leishmania gp63 adhesion site
  20. Expression of the major surface glycoprotein of Leishmania, gp63, in wild-type and sinefungin-resistant promastigotes
  21. NMR study on a SRYD-containing fibronectin-like sequence (250–257) of Leishmania gp63: contribution of residual water in the dimethyl sulfoxide solution structure
  22. Conformational study on a fibronectin-like sequence (250–257) of Leishmania gp63, using 1H-NMR spectroscopy
  23. Substrate-dependent pH optima of gp63 purified from seven strains of Leishmania
  24. Surface Antigens of Leishmania Infantum Identified by Monoclonal Antibodies: Isolation of a Monomeric and an Oligomeric form of a Major L. Infantum Antigen
  25. Leishmania Antigens Probed by Monoclonal Antibodies to Leishmania Membrane and to Acetylcholine Receptor
  26. Common Antigenic Determinants between Acetylcholine Receptor and Protozoan Membranes